Pancreatic neuroendocrine tumors: Entering a new era

Journal of the Pancreas

Volumn 13, Issue 2, 2012, Pages 169-173

  Oberstein, Paul E ^a   Remotti, Helen ^a   Saif, Muhammad Wasif ^a   Libutti, Steven K ^b  

^a New York Presbyterian Hospital ^*  (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Drug therapy; Everolimus; Neuroendocrine tumors; Pancreatic neoplasms; Sunitinib

Indexed keywords

BEVACIZUMAB; CHROMOGRANIN A; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; OCTREOTIDE; PLACEBO; SEROTONIN; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS;

CANCER INCIDENCE; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG APPROVAL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PREVALENCE; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; STOMATITIS; SYMPOSIUM; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; HUMANS; PANCREATIC NEOPLASMS;

EID: 84858683823     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-7.
2. Jensen RT. Carcinoid tumors and the carcinoid syndrome. In: De Vita VTJ, Lawrence, T., Rosenberg, S.A., ed. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, Williams, and Wilkins; 2008.
3. Choti MA, Mayorga MA, Bobiak S, et al. Baseline demographics of patients with neuroendocrine tumors presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database. J Clin Oncol 30, 2012 (suppl 4;abstr 187).
4. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-500.
5. Yao JC, Hassan M, Phan A, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
6. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:108-18.
7. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
8. McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004;27:485-8.
9. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92.
10. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113:1807-43.
11. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005;104:2292-309.
12. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-203.
13. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245-55.
14. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109:1478-86.
15. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
16. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
17. Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Babigumira J, Garrison LP. Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States. J Clin Oncol 2012; 30(Suppl 4):Abstract 226.
18. Raymond E NP, Raoul J, et al. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patient with advanced unresectable neuroendocrine tumors (NET). J Clin Oncol 2011;29(Suppl.):4008.
19. Signorovitch J, Swallow E, Kantor E, et al. Overall survival with everolimus, sunitinb, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials. J Clin Oncol;30, 2012 (suppl 4; abstr 237).
20. Hobday TJ, Qin R, Reidy DL, Moore MJ, Strosberg JR, Kaubisch A, et al. Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J Clin Oncol 2012; 30(Suppl 4):Abstract 260.
21. Bergsland EK, Watt L, Ko AH, Tempero MA, Korn WK, Kelley RK, et al. A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET). J Clin Oncol 2012; 30(Suppl 4):Abstract 285.
22. Yao JC, Hainsworth J, Wolin EM, et al. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). J Clin Oncol 30, 2012 (suppl 4;abstr 157)
23. Alistar AT, Warner R, Moshier E, et al. Biomarkers in pancreatic neuroendocrine tumors. J Clin Oncol 30, 2012 (suppl 4;abstr 166).
24. Bruzoni M, Johnston E, Sasson AR. Pancreatic incidentalomas: clinical and pathologic spectrum. Am J Surg 2008;195:329-32; discussion 32.
25. Yamaguchi T, Machida N, Kasuga A, Takahashi H, Sudo K, Nishina T, et al. Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. J Clin Oncol 2012; 30(Suppl 4):Abstract 274.
26. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
27. Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51:1033-8.